Tumor organoids
Conditions
Interventions
Group 1: After tumor resection or biopsy, fresh tumor tissue that is not required for the clinical pathological work-up is transferred to the laboratory to initiate patient-derived tumor organoids (PD
Sponsors
Universitätsklinikum Heidelberg, Radiologische Klinik, RadioOnkologie und Strahlentherapie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: • patients with solid tumor diseases that undergo tumor resection or biopsy at Heidelberg University Hospital • patients with non-tumor disease that undergo resection of tissue, an organ or diagnostic biopsy at Heidelberg University Hospital • age > 18 years of age • ability of subject to understand character and individual consequences of the clinical trial • written informed consent (must be available before enrolment in the trial)
Exclusion criteria
Exclusion criteria: • refusal of the patients to take part in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The overarching goal is to initiate a biologically personalized radiotherapy (RT) for cancer patients. Hence, it is aimed to 1) establish and refine patient-derived tumor organoids (PDOs) as ex-vivo models of the individual cancer biology 2) use PDOs as models to predict patients’ radiation response for future development of personalized dose prescription and combination therapy approaches 3) dissect the interaction of tumor, microbiome and immune cells in patients and PDOs under RT | — |
Secondary
| Measure | Time frame |
|---|---|
| Expand the predictive value of PDOs with tumor derivates that are dissolved in the patient's blood (so called “liquids”). | — |
Countries
Germany
Contacts
Public ContactThomas Held
Klinik für RadioOnkologie und Strahlentherapie
Outcome results
None listed